Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

Af­ter a drum­beat of fail­ure, set­backs and re­or­ga­ni­za­tions over the last few years, Aduro CEO Stephen Isaacs is hand­ing over his large­ly gut­ted-out shell of a pub­lic com­pa­ny to an­oth­er biotech com­pa­ny and putting up some ques­tion­able as­sets in a go­ing-out-of-busi­ness sale.

Isaacs —who forged a string of high-pro­file Big Phar­ma deals along the way — has wrapped a 13-year run at the biotech with one pro­gram for kid­ney dis­ease go­ing to the new own­ers at Chi­nook Ther­a­peu­tics. A host of once-her­ald­ed as­sets like their STING ag­o­nist pro­gram part­nered with No­var­tis (which dumped their work on ADU-S100 af­ter look­ing over weak clin­i­cal re­sults), the Lil­ly-al­lied cGAS-STING in­hibitor pro­gram and the an­ti-CD27 pro­gram out-li­censed to Mer­ck will all be post­ed for auc­tion un­der a strate­gic re­view process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER